Mario Schlosser

Director Mario Schlosser sells 47,500 OSCR shares for $1,484,013.80 via pre-arranged 10b5-1 plan on July 1, 2026

Director Mario Schlosser executed 3 separate sales totaling 47,500 shares for $1,484,013.80 on 2026-07-01 via a pre-arranged 10b5-1 trading plan adopted on 2026-03-24. His non-derivative holdings in the form of Class B Common Stock (held through the Pizzo-Schlosser Family Dynasty Trust) were reduced to zero shares post-transaction, though his overall beneficial position remains significant at 538,333 shares held through derivative securities in the trust vehicle. The stock is trading at $31.44 currently, near its 52-week high of $33.10 (+28.3% over 30 days and +142.4% over 90 days), suggesting the company has appreciated substantially since the plan was adopted. Because this sale is part of a scheduled 10b5-1 plan—not a discretionary decision—timing inferences are not applicable; however, the context of strong recent price performance and the company's reported $4.6B in quarterly revenue with $679.0M net income (against a history of full-year unprofitability) indicates Oscar Health has achieved material operational improvement that likely drove the recent rally.

Oscar Health Director Mario Schlosser executes 12 scheduled sales totaling 1,027,500 shares for $30.2M near 52-week high

Mario Schlosser, Director at Oscar Health (OSCR), executed 12 separate sales on 2026-06-23 totaling 1,027,500 shares for $30,183,413.04 at a blended average price of $29.38, under a 10b5-1 trading plan adopted on 2026-03-24. These transactions cleared his Table I non-derivative holdings, but substantial derivative and Class B positions remain across 6 ownership vehicles totaling 8,197,085 shares, including 3,740,000 stock options and multiple Class B Common Stock tranches. The stock had risen +31.0% over the prior 30 days and +157.4% over 90 days, sitting -5.6% from its 52-week high of $30.38 at the time of the sales. His 5 prior sells at OSCR showed subsequent 90-day returns ranging from -25.0% to -14.4% across four of those trades, with the most recent showing -25.0%, though those were not necessarily executed under a scheduled plan as this filing is.

OSCR President of Technology Mario Schlosser sells 76,962 shares at $17.01; stock now -24.8% from 52-week high with -10.0% 90-day decline.

Mario Schlosser, President of Technology & CTO, sold 76,962 shares at $17.01 on 2026-01-06, reducing his holdings from 427,142 to 350,180 shares. The sale occurred as Oscar Health stock trades at $16.90, down 24.8% from its 52-week high and down 10.0% over the past 90 days. Notably, Schlosser has executed three separate sales in the past two weeks (2025-12-24, 2026-01-02, and 2026-01-06), suggesting sustained portfolio activity during a period of stock weakness. His cross-ticker track record shows a 66.67% well-timed sell rate with strong average 90-day returns of +38.8%, but this pattern does not apply to his recent Oscar Health activity where prior measurable outcomes have been mixed or not yet complete.

Oscar Health CTO Mario Schlosser sold 234,861 shares for $3,587,707.58 in two transactions Jan 2–5, reducing stake by 40.1%

Mario Schlosser (President of Technology & CTO) sold 234.9K shares across 2 separate transactions—137,933 shares at $15.02 on 2026-01-02 and 96,928 shares at $15.64 on 2026-01-05—for combined proceeds of $3.6M and a blended average price of $15.28. This reduces his position from 585.0K to 350.2K shares (-40.1% reduction). The current price of $16.52 is 26.5% below the 52-week high of $22.47, and Oscar's stock has fallen 24.2% over the past 90 days and 1.5% in the past 30 days. His cross-ticker track record shows 7 prior sells with an average 90-day return of +38.8% and a 90-day well-timed rate of 66.67%, indicating his sells have historically preceded price appreciation. At Oscar specifically, the measurable outcome from his prior sale on 2025-09-22 showed a 90-day return of -19.2% (well-timed), though only 1 of 1 prior Oscar sales have a measurable 90-day outcome. The company posted $3.0B in quarterly revenue and $-137.4M net loss, with a P/E of 150.18, reflecting unprofitability despite strong 56.5% annual revenue growth.

CTO Schlosser sold 38,835 shares of OSCR at $15.00; stock now down 35.4% from 52-week high and 19.2% in 30 days.

Schlosser Mario, President of Technology & CTO, sold 38,835 shares at $15.00 on 2025-12-24, reducing his OSCR holdings by 8.1%. The sale price of $15.00 sits above the current price of $14.51, but the stock has declined 35.4% from its 52-week high of $22.47 and dropped 19.2% over the past 30 days alone. At the same-ticker level, his prior 3 completed trades showed mixed outcomes: two were well-timed by the 90-day measure (30 Sep 2025 sale: 90d return -19.2%; 16 Nov 2023 sale: 90d return +137.3%), while one was poorly timed (15 Aug 2023 sale: 90d return -1.6%). The company reports a P/E of 131.91 and is unprofitable, with a net loss of $-137,450,000.00 in the latest quarter, despite strong 56.5% annual revenue growth. The timing of this December sale, occurring after the stock has already experienced material 30- and 90-day declines, limits the strength of any signal this transaction may convey about near-term confidence levels.